Provident Fund interest in 2009-10 will be 8.5%

Private sector employees have an annual pastime, speculate on how much interest their provident fund balances will earn. This year, they know it at the beginning of the year itself. They have been given some good news, ahead of the budget. The Central Board of Trustees (CBT) has recommended to the government, to continue with last year’s interest rate. They will get an interest rate of 8.5% on their provident fund balances.

Continue Reading

Rail Budget: finances go off track

Today, the Railway Budget 2009-10 was presented by the railway minister Mamata Banerjee. It was her maiden budget and she left no stone unturned to announce populist schemes, the hallmark of every rail minister. When the times were mostly good, as in the previous government’s tenure, it didn’t pinch but in a slowing economy, it is undoing the strong position the railways made for itself in the past five years.
 

Continue Reading

Tech Mahindra’s open offer to Satyam shareholders closes

When Tech Mahindra emerged as the successful bidder for the scam-ridden software company Satyam Computer Services, it seemed like the subsequent open offer would be a success.
 

But Satyam’s share price rose significantly, in the interim, as investors began to regain some confidence in its future, especially after its provisional results for the third quarter were made public. The company’s profitability was much better than what was feared. While the open offer was at Rs 58 the share closed today, the last day of the offer, at Rs 74.
 

Continue Reading

Wockhardt sells animal health business to Vetoquinol

When Wockhardt decided to sell its animal health business, it expected to get about Rs 150 crore for it. When the business was actually sold, to a French company Vetoquinol, the consideration remained undisclosed. So, if it met its target or fell short of it since exceeding it seems unlikely. The pharmaceutical company is selling non-core businesses in a bid to raise cash and lower its bloated debt.

Vetoquinol and what it gets

Continue Reading

Sun Pharma to revise guidance after FDA’s raid on Caraco

Dilip Shanghvi, chairman and managing director, Sun Pharmaceutical Industries, and Sudhir Valia, director held a conference call held to discuss the FDA raid on its US subsidiary Caraco Pharmaceutical Laboratories. This event has come as big blow for Sun. It has withdrawn its current guidance and will issue a revised one, in due course. The issue is expected to have a significant short term impact on Caraco and some adverse impact on Sun’s short term performance too.

Continue Reading

Caraco claims sound financial position, but FDA action will harm performance

Caraco issued a statement on Friday, clarifying its financial position after the FDA raid on its facilities. The company said that the inventory that has been seized by the regulator has a value of about $15-$20mn. It does not affect products sold by Caraco under third-party distribution agreements (such as with Sun Pharmaceutical Industries, its Indian parent company) and also products sold under the Caraco brand, but made by other companies.

Continue Reading